You are cordially invited to join Sidley Breakfast Reception with Korean innovative biopharma companies!
Rebecca Wood, immediate former Chief Counsel to the U.S. FDA under Scott Gottlieb and head of Sidley’s Food, Drug and Medical Device Regulatory practice, and Emily Marden, Sidley counsel with extensive biotech industry experience, will share the latest FDA developments and issues to watch in 2020 for Korean companies, including pathways to approval and exclusivity, as well as accelerated approval trends.
Please note, space for the event is limited.
For questions, please contact sfevents@sidley.com.
